The Writing Committee of the Report on Cardiovascular Health Diseases in China, 2023, Interpretation of Report on Cardiovascular Health and Diseases in China 2022. Chinese Journal of Cardiovascular Medicine, 28(04): 297–312.

Libby P, Buring JE, Badimon L, et al., 2019, Atherosclerosis. Nat Rev Dis Primers, 5(1): 56.

Libby P, 2021, The Changing Landscape of Atherosclerosis. Nature, 592(7855): 524–533.

Lin J, Wang Q, Zhou S, et al., 2022, Tetramethylpyrazine: A Review on Its Mechanisms and Functions. Biomedicine and Pharmacotherapy, (150): 113005.

Xu P, Zhai Y, Wang J, 2018, The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis. Int J Mol Sci, 19(4): 1260.

Fu R, Zhang Y, Guo Y, et al., 2014, Digital Gene Expression Analysis of the Pathogenesis and Therapeutic Mechanisms of Ligustrazine and Puerarin in Rat Atherosclerosis. Gene, 552(1): 75–80.

Zhang Y, Ren P, Kang Q, et al., 2017, Effect of Tetramethylpyrazine on Atherosclerosis and SCAP/SREBP-1c Signaling Pathway in ApoE-/- Mice Fed with a High-Fat Diet. Evidence-Based Complementary and Alternative Medicine, (2017): 1–8.

Brown MS, Radhakrishnan A, Goldstein JL, 2018, Retrospective on Cholesterol Homeostasis: The Central Role of Scap. Annual Review of Biochemistry, 87(1): 783–807.

Jiang F, Qian J, Chen S, et al., 2011, Ligustrazine Improves Atherosclerosis in Rat Via Attenuation of Oxidative Stress. Pharmaceutical biology, 49(8): 856–863.

Wang G, Shi C, Sun M, et al., 2013, Tetramethylpyrazine Attenuates Atherosclerosis Development and Protects Endothelial Cells from ox-LDL. Cardiovascular Drugs and Therapy, 27(3): 199–210.

Duan J, Xiang D, Luo H, et al., 2017, Tetramethylpyrazine Suppresses Lipid Accumulation in Macrophages Via Upregulation of the ATP-Binding Cassette Transporters and Downregulation of Scavenger Receptors. Oncol Rep, 38(4): 2267–2276.

Wolf D, Ley K, 2019, Immunity and Inflammation in Atherosclerosis. Circulation Research, 124(2): 315–327.

Falck-Hansen M, Kassiteridi C, Monaco C, 2013, Toll-Like Receptors in Atherosclerosis. International Journal of Molecular Sciences, 14(7): 14008–14023.

Li X, He J, Liu H, et al., 2009, Tetramethylpyrazine Suppresses Interleukin-8 Expression in LPS-Stimulated Human Umbilical Vein Endothelial Cell by Blocking ERK, p38 and Nuclear Factor-KappaB Signaling Pathways. Journal of Ethnopharmacology, 125(1): 83–89.

Chen J, Wang H, Gao C, et al., 2019, Tetramethylpyrazine Alleviates LPS-Induced Inflammatory Injury in HUVECs by Inhibiting Rho/ROCK Pathway. Biochemical and Biophysical Research Communications, 514(1): 329–335.

Chrissobolis S, Miller AA, Drummond GR, et al., 2011, Oxidative Stress and Endothelial Dysfunction in Cerebrovascular Disease. Front Biosci (Landmark Ed), 16(5): 1733–1745.

Forstermann U, Xia N, Li H, 2017, Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circulation Research, 120(4): 713–735.

Li WM, Liu HT, Li XY, et al., 2010, The Effect of Tetramethylpyrazine on Hydrogen Peroxide-Induced Oxidative Damage in Human Umbilical Vein Endothelial Cells. Basic and Clinical Pharmacology and Toxicology, 106(1): 45–52.

Fan X, Wang E, He J, et al., 2019, Ligustrazine Protects Homocysteine-Induced Apoptosis in Human Umbilical Vein Endothelial Cells by Modulating Mitochondrial Dysfunction. J Cardiovasc Transl Res, 12(6): 591–599.

Ni X, Wong SL, Wong CM, et al., 2014, Tetramethylpyrazine Protects against Hydrogen Peroxide-Provoked Endothelial Dysfunction in Isolated Rat Aortic Rings: Implications for Antioxidant Therapy of Vascular Diseases. Evidence-Based Complementary and Alternative Medicine, (2014): 1–10.

Li H, Yang M, 2022, Ligustrazine Activates the PPAR-Gamma Pathway and Plays a Protective Role in Vascular Calcification. Vascular, 30(6): 1224–1231.

Camare C, Pucelle M, Negre-Salvayre A, et al., 2017, Angiogenesis in the Atherosclerotic Plaque. Redox Biol, (12): 18–34.

Wang L, Li G, Chen Q, et al., 2015, Octanoylated Ghrelin Attenuates Angiogenesis Induced by ox-LDL in Human Coronary Artery Endothelial Cells Via the GHSR1a-Mediated NF-KappaB Pathway. Metabolism, 64(10): 1262–1271.

Apte RS, Chen DS, Ferrara N, 2019, VEGF in Signaling and Disease: Beyond Discovery and Development. Cell, 176(6): 1248–1264.

Park JA, Kwon YG, 2018, Hippo-YAP/TAZ Signaling in Angiogenesis. BMB Rep, 51(3): 157–162.

Yuan R, Shi W, Xin Q, et al., 2018, Tetramethylpyrazine and Paeoniflorin Inhibit Oxidized LDL-Induced Angiogenesis in Human Umbilical Vein Endothelial Cells Via VEGF and Notch Pathways. Evidence-Based Complementary and Alternative Medicine, (2018): 1–12.

Zhu X, Shan Y, Yu M, et al., 2021, Tetramethylpyrazine Ameliorates Peritoneal Angiogenesis by Regulating VEGF/Hippo/YAP Signaling. Frontiers in Pharmacology, (12): 649581.

Sheu JR, Kan YC, Hung WC, et al., 1997, Mechanisms Involved in the Antiplatelet Activity of Tetramethylpyrazine in Human Platelets. Thromb Res, 88(3): 259–270.

Zhang Y, Ma XJ, Guo CY, et al., 2016, Pretreatment with a Combination of Ligustrazine and Berberine Improves Cardiac Function in Rats with Coronary Microembolization. Acta Pharmacol Sin, 37(4): 463–472.

Sheu JR, Kan YC, Hung WC, et al., 2000, The Antiplatelet Activity of Tetramethylpyrazine is Mediated Through Activation of NO Synthase. Life Sci, 67(8): 937–947.

Li L, Chen H, Shen A, et al., 2019, Ligustrazine Inhibits Platelet Activation Via Suppression of the Akt Pathway. Int J Mol Med, 43(1): 575–582.

Vinchi F, Porto G, Simmelbauer A, et al., 2020, Atherosclerosis is Aggravated by Iron Overload and Ameliorated by Dietary and Pharmacological Iron Restriction. European Heart Journal, 41(28): 2681–2695.

Zhou Q, Chen S, Li H, et al., 2020, Tetramethylpyrazine Alleviates Iron Overload Damage in Vascular Endothelium Via Upregulating DDAHII Expression. Toxicology in Vitro, (65): 104817.

Zhang M, Sun MY, Guo CY, et al., 2019, Effect of Tetramethylpyrazine and Hyperlipidemia on Hepcidin Homeostasis in Mice. Int J Mol Med, 43(1): 501–506.